Biotech firm Intellia is pushing forward with late-stage gene editing trials, even as investors remain cautious after a steep share price drop and persistent cash burn.

Exploration breakthroughs, rising receipts, and healthy cash reserves set the pace for several Australian mining firms this quarter.

America’s health insurance leader faces a tough year as rising Medicare costs, management shakeups and regulatory scrutiny leave investors weighing a future rebound against lingering risks.

A sharp drop in metal prices, US tariffs, and weak Chinese demand have weighed on Glencore, but a capital return and hopes for a copper rebound could lift fortunes later this year.

What’s going on here? A new surge in municipal bond issues across the US is pushing climate risk into the spotlight, as fresh research shows extreme weather threats are now a major factor for ...

Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. RBC Capital Markets sees J.M. Smucker's Uncrustables brand as a hidden gem, pinpointing it as a crucial driver ...

What’s going on here? Blackstone and TPG are in talks to acquire portions of H&R Real Estate Investment Trust's $7.67 billion portfolio, attracting attention from investors in the US and Canada. What ...

Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. Another day, another tariff threat. The US president turned up the trade tension dial yet again, announcing ...

The Daily Brief is a podcast that covers the top stories in finance each day – hit play to listen or follow the links below to read. Today's Stories American Copper Prices Hit A Record High On The ...

What’s going on here? Bitcoin just blasted beyond $118,000 on Friday, as traders scrambled for coins ahead of what’s expected to be a big week for crypto. What does this mean? US spot bitcoin exchange ...

Tech stocks cushion the Nikkei's fall, but tariff concerns hit Fast Retailing hard in a mixed market.

What’s going on here? Biotech stocks are climbing as Recursion Pharmaceuticals and Rallybio make big strategic moves, while Progyny excites investors with positive Q2 forecasts. Recursion ...